Understanding Quality of Life in Hereditary Angioedema: Insights from Recent Research

被引:0
作者
Ozdel Ozturk, Betul [1 ]
Soyyigit, Sadan [1 ,2 ]
机构
[1] Ankara Bilkent City Hosp, Dept Immunol & Allerg Dis, Ankara, Turkiye
[2] Ankara Yildirim Beyazit Univ, Sch Med, Dept Immunol & Allerg Dis, Ankara, Turkiye
来源
ASTHMA ALLERGY IMMUNOLOGY | 2024年
关键词
Hereditary angioedema; quality of life; anxiety and depression; disease burden; ECONOMIC BURDEN; CHILDREN; EPIDEMIOLOGY; PROPHYLAXIS; PREVENTION; MANAGEMENT; THERAPY; ILLNESS; ATTACKS; COSTS;
D O I
10.21911/aai.2024.643
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of localized edema, significantly impairing the health-related quality of life (HRQoL) in affected individuals. The recurrent and unpredictable episodes of angioedema lead to considerable pain, discomfort, and distress, directly affecting physical functioning and daily activities. Many patients report severe emotional burdens, including anxiety and depression, stemming from both the unpredictability of attacks and the fear of potential hereditary transmission to offspring. In children, the impact of HAE is particularly pronounced, affecting social development and educational attainment. Frequent hospital visits and school absenteeism hinder their academic performance and social interactions, which are crucial for their emotional and psychological development. Psychological assessments have shown elevated anxiety levels in children with HAE, correlating this distress with decreased overall quality of life. For adults, the ramifications of HAE extend into social and economic dimensions. Adults frequently face interruptions in their employment due to the disease, leading to economic strain characterized by high medical costs and lost productivity. There is a notable relationship between the frequency of attacks and overall HRQoL, where higher attack rates correlate with lower scores in the emotional, social, and physical domains. The effectiveness of prophylactic treatments has been documented, indicating that reductions in attack frequency contribute to improved HRQoL. However, barriers such as medication access, side effects of treatments, and financial burdens remain prevalent. Despite advancements in understanding and managing HAE, the multifaceted impact of the disease necessitates comprehensive care strategies that address not only the physical symptoms but also the psychological and social dimensions of living with HAE.
引用
收藏
页码:003 / 013
页数:11
相关论文
共 37 条
[31]   Critical appraisal of androgen use in hereditary angioedema: a systematic review [J].
Riedl, Marc A. .
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2015, 114 (04) :281-+
[32]   Hereditary Angioedema: Diagnosis, Clinical Implications, and Pathophysiology [J].
Sinnathamby, Evan S. ;
Issa, Peter P. ;
Roberts, Logan ;
Norwood, Haley ;
Malone, Kevin ;
Vemulapalli, Harshitha ;
Ahmadzadeh, Shahab ;
Cornett, Elyse M. ;
Shekoohi, Sahar ;
Kaye, Alan D. .
ADVANCES IN THERAPY, 2023, 40 (03) :814-827
[33]   The impact of hereditary angioedema on quality of life and family planning decisions [J].
Tuncel, Ozlem Kuman ;
Gokmen, Nihal Mete ;
Demur, Ece ;
Gulbahar, Okan ;
Pirildar, Sebnem .
INTERNATIONAL JOURNAL OF PSYCHIATRY IN MEDICINE, 2019, 54 (06) :377-394
[34]   Health-related quality of life with hereditary angioedema following prophylaxis with subcutaneous C1-inhibitor with recombinant hyaluronidase [J].
Weller, Karsten ;
Maurer, Marcus ;
Fridman, Moshe ;
Supina, Dylan ;
Schranz, Jennifer ;
Magerl, Markus .
ALLERGY AND ASTHMA PROCEEDINGS, 2017, 38 (02) :143-151
[35]   Hereditary Angioedema [J].
Wilkerson, R. Gentry ;
Moellman, Joseph J. .
EMERGENCY MEDICINE CLINICS OF NORTH AMERICA, 2022, 40 (01) :99-118
[36]   Economic costs associated with acute attacks and long-term management of hereditary angioedema [J].
Wilson, David A. ;
Bork, Konrad ;
Shea, Elizabeth P. ;
Rentz, Anne M. ;
Blaustein, Marc B. ;
Pullman, William E. .
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2010, 104 (04) :314-U127
[37]   Tranexamic acid as maintenance treatment for non-histaminergic angioedema: analysis of efficacy and safety in 37 patients [J].
Wintenberger, C. ;
Boccon-Gibod, I. ;
Launay, D. ;
Fain, O. ;
Kanny, G. ;
Jeandel, P. Y. ;
Martin, L. ;
Gompel, A. ;
Bouillet, L. .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2014, 178 (01) :112-117